Luminary Learning Gastrointestinal Disorder- Issue 1

28  • LUMINARY LEARNING: GASTROINTESTINAL DISORDERS 56. Tougas G, Snape WJ Jr, Otten MH, Earnest DL et al (2002) Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 16:1701–1708. 57. Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358:2344–2354. 58. Quigley EM, Vandeplassche L, Kerstens R, Ausma J (2009) Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation—A 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 29:315–328. 59. Tack J, van Beyens G, Kerstens R et al (2009) Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58:357–365. 60. Mugie SM, Korczowski B, Bodi P, Green A et al (2014) Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology 147:1285–1295. 61. Johnston JM, Kurtz CB, Drossman DA, Lembo AJ et al (2009) Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol 104:125–132. 62. Rao S, Lembo AJ, Shiff SJ, Lavins BJ et al (2012) A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 107:1714–1724. 63. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ et al (2012) Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 107:1702–1712. 64. Yu SW, Rao SS (2014) Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide. Therap Adv Gastroenterol 7:193–205. 65. Wilson N, Schey R (2015) Lubiprostone in constipation: clinical evidence and place in therapy. Ther Adv Chronic Dis 6:40–50. 66. Jakab RL, Collaco AM, Ameen NA (2012) Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility. Dig Dis Sci 57:2826–2845. 67. Johanson JF, Ueno R (2007) Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 25:1351–1361. 68. Johanson JF, Morton D, Geenen J, Ueno R (2008) Multicenter, 4-week, double-blind, randomized, placebo- controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 103:170–177. 69. Johanson JF, Drossman DA, Panas R, Wahle A et al (2008) Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 27:685–696. 70. Trinkley KE, Nahata MC (2014) Medication management of irritable bowel syndrome. Digestion 89:253–267. 71. Mosinska P, Salaga M, Fichna J (2016) Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review. Expert Opin Investig Drugs 25:275–286. 72. Deiana S, Gabbani T, Bagnoli S, Annese V (2015) Emerging drug for diarrhea predominant irritable bowel syndrome. Expert Opin Emerg Drugs 20:247–261. 73. AlamMS, Roy PK, MiahAR, Mollick SH et al (2013) Efficacy of Peppermint oil in diarrhea predominant. Mymensingh Med J 22:27–30. 74. Khanna R, Macdonald JK, Levesque BG (2014) Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 48:505–512. 75. Ma XP, Hong J, An CP, Zhang D et al (2014) Acupuncture-moxibustion in treating irritable bowel syndrome: how does it work? World J Gastroenterol 20:6044–6054. 76. Manheimer E, Wieland LS, Cheng K, Li SM et al (2012) Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 107:835–847. 77. Stuardi T, MacPherson H (2012) Acupuncture for irritable bowel syndrome: diagnosis and treatment of patients in a pragmatic trial. J Altern Complement Med 18:1021–1027. 78. Miller V, Carruthers HR, Morris J, Hasan SS et al (2015) Hypnotherapy for irritable bowel syndrome: an audit of one thousand adult patients. Aliment Pharmacol Ther 41:844–855. 79. Palsson OS (2015) Hypnosis treatment of gastrointestinal disorders: A comprehensive review of the empirical evidence. Am J Clin Hypn 58:134–158. Source: Sałaga M, Mosińska P. Pharmacological and clinical treatment of irritable bowel syndrome. In: Fichna J. (ed). Introduction to Gastrointestinal Diseases Vol. 1. 1st ed. Switzerland: Springer International Publishing; 2016, pp. 43-61. DOI 10.1007/978-3-319- 49016-8_4. © Springer International Publishing AG 2017.